- Home
- BRKR vs RYTM Comparison
BRKR vs RYTM Comparison
Compare BRKR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRKR | RYTM |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.4B |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRKR | RYTM |
|---|---|---|
| Price | $33.74 | $86.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $49.54 | ★ $129.93 |
| AVG Volume (30 Days) | ★ 2.2M | 709.0K |
| Earning Date | 05-04-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,895,600,000.00 | N/A |
| Revenue This Year | $6.27 | $57.46 |
| Revenue Next Year | $3.78 | $85.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.53 | $45.91 |
| 52 Week High | $56.22 | $122.20 |
Technical Indicators
Market Signals| Indicator | BRKR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 37.19 |
| Support Level | $29.54 | $85.59 |
| Resistance Level | $35.15 | $96.92 |
| Average True Range (ATR) | 1.49 | 5.11 |
| MACD | -0.21 | -0.45 |
| Stochastic Oscillator | 5.10 | 21.76 |
Price Performance
Historical ComparisonAbout BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.